** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O rise 13.8% to $352.3
** Co reports Q4 sales of $103.3 mln from its fatty liver disease drug Rezdiffra, beating analysts' estimate of $71.95 mln as per data compiled by LSEG
** Two-year data from a late-stage study evaluating Rezdiffra shows it helped significantly reduce liver stiffness in patients with metabolic dysfunction-associated steatohepatitis (MASH)
** Says 51% of patients enrolled in the trial achieved 25% or greater reduction in liver stiffness -MDGL
** Significant reduction of liver stiffness has been associated with reduced progression to end-stage liver disease -MDGL
** MASH is a serious condition that causes excess build up of fat in the liver and causes inflammation and fibrosis, or scarring, of the organ
** Stock has risen 33% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。